Stockscreener 앱 받기
1.43
2.72%
-0.04
시간 외 거래:
1.44
0.01
+0.70%
전일 마감가:
$1.47
열려 있는:
$1.46
하루 거래량:
460.31K
Relative Volume:
0.36
시가총액:
$34.82M
수익:
$752.00K
순이익/손실:
$-68.21M
주가수익비율:
-0.1475
EPS:
-9.6977
순현금흐름:
$-58.21M
1주 성능:
-17.34%
1개월 성능:
-12.80%
6개월 성능:
-44.57%
1년 성능:
-37.55%
1일 변동 폭
$1.40
$1.47
1주일 범위
$1.40
$1.719
52주 변동 폭
$1.17
$8.08
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.43 | 35.79M | 752.00K | -68.21M | -58.21M | -9.6977 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.42B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.64B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 44.33B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.51B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 22.84B | 3.18B | 1.33B | 1.04B | 27.90 |
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Rodman & Renshaw | Buy |
| 2024-02-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-06 | 재확인 | BofA Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-30 | 개시 | Goldman | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-04 | 개시 | Guggenheim | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
BioXcel Therapeutics $9.75M Class Action Settlement - Claim Depot
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc. - GlobeNewswire Inc.
If You Invested $1,000 in Bioxcel Therapeutics Inc (BTAI) - Stock Titan
Stock Ratings | Baird Bank raises CRCL's price target to $138; Rodman & Renshaw initiates coverage of BTAI with a "buy" recommendation and a $17 price target, representing a potential upside of 882.66%. - Sahm
Why are BioXcel Therapeutics shares down Friday? - MSN
Why did BTAI stock surge 20% in pre-market today? - MSN
Buyout Rumor: Whats BioXcel Therapeutics Incs historical return2026 Trade Ideas & High Accuracy Swing Entry Alerts - baoquankhu1.vn
BioXcel Therapeutics Inc (BTAI) Stock Price, Quote, News & History - Benzinga
BioXcel Therapeutics stock initiated with buy rating at Rodman By Investing.com - Investing.com Canada
BioXcel Therapeutics stock initiated with buy rating at Rodman - Investing.com
BTAI: BioXcel Therapeutics Initiates Coverage with 'Buy' Rating - GuruFocus
This Ingredion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
BioXcel Therapeutics (BTAI) CSO converts 68 RSUs into 6,520-share holding - Stock Titan
BioXcel Therapeutics (BTAI) officer converts 68 RSUs into common shares - Stock Titan
BioXcel Therapeutics (BTAI) CEO Vimal Mehta exercises RSUs for 383 shares - Stock Titan
BioXcel Therapeutics closes $8M registered direct offering - Investing.com Australia
Press Release: BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering - 富途牛牛
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs - Yahoo Finance
BioXcel Therapeutics raises $8M in stock offering - Hartford Business Journal
BioXcel Therapeutics Announces Registered Direct Offering and Warrant Amendment – SEC 8-K Filing March 2026 - Minichart
BioXcel Therapeutics closes $8M registered direct offering By Investing.com - Investing.com South Africa
BioXcel Therapeutics Announces Registered Direct Equity Financing - TipRanks
BioXcel Therapeutics, Inc. Completes $8 Million Registered Direct Offering of Common Stock and Warrants - Quiver Quantitative
BioXcel Therapeutics Closes $8.0 Million Direct Offering - marketscreener.com
BioXcel Therapeutics (NASDAQ: BTAI) completes $7.8M equity and warrant financing - Stock Titan
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering - ChartMill
BioXcel Therapeutics raises $8M in registered direct offering - Investing.com Australia
BioXcel Therapeutics (NASDAQ: BTAI) raises ~$7.3M with 2.48M share offering - Stock Titan
BioXcel Therapeutics raises $8M in registered direct offering By Investing.com - Investing.com India
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering - The Manila Times
BioXcel raises $8M, reprices warrants in new share sale - Stock Titan
Aug Technicals: Is BioXcel Therapeutics Inc benefiting from interest rate changesQuarterly Risk Review & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Bank of America Securities Sticks to Its Sell Rating for Bioxcel Therapeutics (BTAI) - The Globe and Mail
Why Are BioXcel Therapeutics Shares Down Friday? - Benzinga
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal - Sahm
BioXcel Therapeutics Seeks Market Expansion amid Financial Struggles - timothysykes.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
BioXcel Therapeutics Stock Soars Amid New Drug Approval Speculation - StocksToTrade
BTAI Stock Gained 5% TodayWhat's The Latest On Its Opioid Withdrawal Treatment? - Stocktwits
BioXcel Therapeutics (BTAI) Target Price Lowered by HC Wainwrigh - GuruFocus
BioXcel Therapeutics shares rise 2.7% as experimental opioid withdrawal drug shows benefit in mid-stage trial - marketscreener.com
BioXcel Therapeutics Achieves Milestone with Igalmi’s Market Study - timothysykes.com
BioXcel Therapeutics Stock Rallies Opioid Study Success - Benzinga
Why Did BTAI Stock Surge 20% In Pre-Market Today? - Asianet Newsable
BioXcel Therapeutics (BTAI) Reports Promising Phase 2 Results fo - GuruFocus
BTAI Stock Surges Pre-Market After On Positive Trial Results For Opioid Withdrawal Treatment - Stocktwits
BioXcel Therapeutics shares rise 21.1% premarket as experimental opioid withdrawal drug shows benefit in mid-stage trial - marketscreener.com
BioXcel Therapeutics rises amid sector rotation - Intellectia AI
Bioxcel Therapeutics announces positive Phase 2 topline results from Columbia University-led study of BXCL501 for treatment of opioid withdrawal - marketscreener.com
BioXcel reports positive Phase 2 data for opioid withdrawal drug By Investing.com - Investing.com UK
Bioxcel Therapeutics Announces Positive Phase 2 Topline Results From Columbia University-Led Study Of BXCL501 For Treatment Of Opioid Withdrawal - TradingView
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.75%
1.88%
자본화:
|
볼륨(24시간):